Krassas, G. E. “Thyroid Disease and Female Reproduction”. Fertility and Sterility 74, no. 6 (2000): 1063–70.

Lauritano, E., et al. “Association Between Hypothyroidism and Small Intestinal Bacterial Overgrowth”. Journal of Clinical Endocrinology and Metabolism 92, no. 11 (2007): 4180–84.

Mackawy, A. M. H., et al. “Vitamin D Deficiency and Its Association with Thyroid Disease”. International Journal of Health Sciences 7, no. 3 (2013): 267–75.

Mansournia, N., et al. “The Association Between Serum 25OHD Levels and Hypothyroid Hashimoto’s Thyroiditis”. Journal of Endocrinological Investigation 37, no. 5 (2014): 473–76.

Olsson, E. M. G., et al. “A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Standardised Extract SHR-5 of the Roots of Rhodiola Rosea in the Treatment of Subjects with Stress-Related Fatigue”. Planta Medica 75 (2009): 105–12.

Ongphiphadhanakul, B., et al. “Tumor Necrosis Factor-Alpha Decreases Thyrotropin-Induced 5’-Deiodinase Activity in FRTL-5 Thyroid Cells”. European Journal of Endocrinology 130, no. 5 (1994): 502–7.

Palmery, M., et al. “Oral Contraceptives and Changes in Nutritional Requirements”. European Review for Medical and Pharmacological Sciences 17, no. 13 (2013): 1804–13.

Peterson, A. M., et al. “The Anti-Inflammatory Effect of Exercise”. Journal of Applied Physiology 98, no. 4 (2005): 1154–62.

Ramya, M. R., et al. “Menstrual Disorders Associated with Thyroid Dysfunction”. International Journal of Reproduction, Contraception, Obstetrics, and Gynecology 6, no. 11 (2017): 5113–17. http://www.ijrcog.org/index.php/ijrcog/article/viewFile /3718/2946.

Rettori, V., et al. “Central Action of Interleukin-1 in Altering the Release of TSH, Growth Hormone, and Prolactin in the Male Rat”. Journal of Neuroscience Research 18, no. 1 (1987): 179–83.

Sapolsky, R. M., et al. “The Neuroendocrinology of Stress and Aging: The Glucocorticoid Cascade Hypothesis”. Endocrine Reviews 7, no. 3 (1986): 284–301.

Sørensen, C. J., et al. “Combined Oral Contraception and Obesity Are Strong Predictors of Low Grade Inflammation in Healthy Individuals: Results from the Danish Blood Donor Study (DBDS)”. PLoS One 9, no. 2 (2014): e88196.

Stagnaro-Green, A. “Approach to the Patient with Postpartum Thyroiditis”. Journal of Clinical Endocrinology and Metabolism 97, no. 2 (2012): 334–42.

Steingold, K. A., “Comparison of Transdermal to Oral Estradiol Administration on Hormonal Hepatic Parameters in Women with Premature Ovarian Failure”. Journal of Clinical Endocrinology and Metabolism 73, no. 2 (1991): 275–80.

Stojanovich, L., et al. “Stress as a Trigger of Autoimmune Disease”. Autoimmunity Reviews 7, no. 3 (2008): 209–13.

Surks, M. I., et al. “Drugs and Thyroid Function”. New England Journal of Medicine 333, no. 25 (1995): 1688–94.

Torp, V. J. “Effect of Oral Contraceptive Agents on Vitamins and Mineral Requirements”. Journal of the American Dietetic Association 76, no. 6 (1980): 581–84.

Verlarde-Mayol, C., et al. “Pernicious Anemia and Autoimmune Thyroid Disease in Elderly People”. [In Spanish.] Revista Española de Geriatría y Gerontología 50, no. 3 (2015): 126–28.

Walter, K. N., et al. “Elevated Thyroid Stimulating Hormone Is Associated with Elevated Cortisol in Healthy Young Men and Women”. Thyroid Research 5 (2012): 13.

Webb, J. L. “Nutritional Effects of Oral Contraceptive Use: A Review”. Journal of Reproductive Medicine 25, no. 4 (1980): 150–56. Westhof, C., et al. “Using Changes in Binding Globulins to Assess Oral Contraceptive Compliance”. Contraception 87, no. 2 (2013): 176–81.

Woodruf, S. C., et al. “Mindfulness and Anxiety”. In The Wiley Blackwell Handbook of Mindfulness, edited by A. Ie, C. T. Ngnoumen, and E. J. Langer, ch. 37. New York: John Wiley, 2014.

8. Разберите свой метаболический кавардак

Abdollahi, M., et al. “Obesity: Risk of Venous Thrombosis and the Interaction with Coagulation Factor Levels and Oral Contraceptive Use”. Thrombosis and Haemostasis 89, no. 3 (2003): 493–98.

Alvarez, J. A., et al. “Role of Vitamin D in Insulin Secretion and Insulin Sensitivity for Glucose Homeostasis”. International Journal of Endocrinology (2010): 351385.

Bakir, R., et al. “Lipids, Lipoproteins, Arterial Accidents, and Oral Contraceptives”. [In French.] Contraception, Fertilité, Sexualité 14, no. 1 (1986): 81–87.

Bloemenkamp, K. W., et al. “Risk of Venous Thrombosis with Use of Current Low-Dose Oral Contraceptives Is Not Explained by Diagnostic Suspicion and Referral Bias”. Archives of Internal Medicine 159, no. 1 (1999): 65–70.

Bultman, S. J. “Emerging Roles of the Microbiome in Cancer”. Carcinogenesis 35, no. 2 (2014): 249–55.

Bushnell, C. D. “Stroke in Women: Risk and Prevention Throughout the Lifespan”. Neurologic Clinics 26, no. 4 (2008): 1161-xi.

Cauci, S., et al. “Effects of Third-Generation Oral Contraceptives on High-Sensitivity C-Reactive Protein and Homocysteine in Young Women”. Obstetrics and Gynecology 111, no. 4 (2008): 857–64.

Centers for Disease Control. “Long – Term Oral Contraceptive Use and the Risk of Breast Cancer. The Centers for Disease Control Cancer and Steroid Hormone Study”. JAMA 249, no. 12 (1983): 1591–95.

Chasan-Taber, L., et al. “Epidemiology of Oral Contraceptives and Cardiovascular Disease”. Annals of Internal Medicine 128, no. 6 (1998): 467–77.

Chen, L., et al. “Mechanisms Linking Inflammation to Insulin Resistance”. International Journal of Endocrinology (2015): 508409.

Cummings, S. R., et al. “Prevention of Breast Cancer in Postmenopausal Women: Approaches to Estimating and Reducing Risk”. Journal of the National Cancer Institute 101, no. 6 (2009): 384–98.

De Bastos, M., et al. “Combined Oral Contraceptives: Venous Thrombosis”. Cochrane Database of Systematic Reviews 3, no. 3 (2014): CD010813.

De Bruijn, S. F., et al. “Case-Control Study of Risk of Cerebral Sinus Thrombosis in Oral Contraceptive Users and in [Correction of Who Are] Carriers of Hereditary Prothrombotic Conditions. The Cerebral Venous Sinus Thrombosis Study Group”. British Medical Journal 316, no. 7131 (1998): 589–92.

Diab, K. M., et al. “Contraception in Diabetic Women: Comparative Metabolic Study of Norplant, Depot Medroxyprogesterone Acetate, Low Dose Oral Contraceptive Pill and CuT380A”. Journal of Obstetrics and Gynaecology Research 26, no. 1 (2000): 17–26.

Dinger, J. C., et al. “The Safety of a Drospirenone-Containing Oral Contraceptive: Final Results from the European Active Surveillance Study on Oral Contraceptives Based on 142,475 Women – Years of Observation”. Contraception 75, no. 5 (2007): 344–54.

Duarte, C., et al. “Oral Contraceptives and Systemic Lupus Erythematosus: What Should We Advise to Our Patients?” Acta Reumatológica Portuguesa 35, no. 2 (2010): 133–40. European Medicines Agency. “PhVWP Monthly Report on Safety Concerns, Guidelines, and General Matters”. No. 1201 (January 2012). http://www.ema.europa.eu/docs/en_GB /document_library/Report/2012/01/WC500121387.pdf.